Navigation Links
Most Off-Label Cancer Drug Use for Palliative Care

International review finds it's an accepted treatment in adults as well as children

MONDAY, Oct. 27 (HealthDay News) -- Between 1990 and 2002, off-label use of anticancer drugs in adults and children ranged between 6.7 percent and 33.2 percent, and most of that off-label use was for palliative care, say researchers who reviewed published studies from a number of countries.

In off-label use, a drug is used to treat conditions that aren't described on the official labeling created when a drug is approved by a regulatory agency such as the U.S. Food and Drug Administration.

Although off-label use of cancer drugs has been reported for most types of cancer, it's most common among patients with metastatic or advanced cancer who are receiving palliative care, noted study author Dr. Dominique Leveque, of the Hopital Hautepierre in Strasbourg, France.

While these patients aren't generally expected to experience clinical benefit, there are circumstances in which off-label anticancer drugs are accepted as the standard of care, such as the use of high-dose carboplatin in some childhood cancers.

But safety is a concern in off-label use, because there's likely little information about tolerance or side effects associated with this kind of use, Leveque said.

He concluded that more research into the extent of off-label use of anticancer drugs is needed and that accurate and unbiased data is urgently required to help doctors make treatment decisions.

The review was published in the November issue of The Lancet Oncology.

More information

The American Cancer Society has more about off-label drug use.

-- Robert Preidt

SOURCE: The Lancet Oncology, news release, Oct. 27, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Abortion drugs off-label use may have led to deaths
3. Off-Label Drug Use Needs Strong Oversight
4. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
5. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Study looks at off-label use of biliary stents
9. Get Screened Video Contest Throws a Spotlight on the Importance of Colorectal-Cancer Screening
10. MicroRNAs make for safer cancer treatments
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: